MTM(SH:688029) 梧桐树下V·2025-06-30 10:09Core Viewpoint - The article discusses the acquisition of 51% stake in CME by Nanwei Medical, highlighting the strategic importance of expanding overseas channels and enhancing market share in Europe [4][5][12]. Group 1: Transaction Background and Purpose - The medical device market in China is becoming increasingly competitive, prompting companies to seek growth in overseas markets where pricing is more stable due to commercial insurance [5]. - Nanwei Medical has prioritized overseas channel development, establishing subsidiaries in the US and Europe, and has made several acquisitions to enhance its direct sales channels [6][5]. Group 2: Transaction Details - Nanwei Medical plans to acquire CME for a maximum of €3.672 million (approximately ¥28.95 million), with the transaction not constituting a major asset restructuring [12]. - CME, a subsidiary of Creo, specializes in the sales of medical devices, with a significant portion of its revenue coming from products that align with Nanwei Medical's offerings [10][9]. Group 3: Financial Data - Recent financial data for Nanwei Medical shows total assets of approximately ¥441.57 million and net profit of ¥31.99 million for the first half of 2024 [8]. - CME's financials indicate total assets of €2.2637 million and net profit of €346.8 thousand for the first half of 2024 [11]. Group 4: Transaction Characteristics - The acquisition process was simplified as it did not require shareholder approval, allowing for a quicker decision-making process [13]. - The transaction is seen as a strategic move to enhance Nanwei Medical's sales capabilities in Europe and improve its competitive position [15].